Financial Incentives for Low Socioeconomic Diabetic Patients
NCT ID: NCT03506230
Last Updated: 2018-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
180 participants
INTERVENTIONAL
2018-11-25
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Candidates that do not have a recent HbA1c result (from the last month) will be referred to perform a blood test. Only patients with an updated result of 8.5% or higher, will be included in the study. The participants will receive explanations from the research staff or the medical professionals at the clinic. General recommendations for diabetes care will be provided orally, and a written summary will be given. Contact details with the research staff will be provided as well.
All participants will be contacted by phone to inform them of their group membership within three days of the recruitment, or 3 days after receiving the result of the blood test. The information will be delivered by a member of the research team that will not know the participants. The result will be sent by mail as well.
The incentives group participants will be told they will receive a bonus to buy their medications at the designated pharmacies. After three months, if they reduce their HBA1c by 0.7% compared to the previous test, or if their HbA1c level is reduced to 7.5% or below, they will get a bonus of up to 100 ILS (30$) every month, for the next three months depending on the total amount of their purchased medicine that month. Six months after entering the trial they will be entitled to a bonus for one additional month if they have reduced their HbA1c level by 0.3% compared to the last test. The bonus can be used to pay for chronic prescription drugs for diabetes, hypertension (HTN) or hyperlipidemia those who are included in the Israeli "health basket," or not included.
The standard treatment group will buy medications as usual. All participants will be encouraged to get their treatment and prescriptions from their physician, and to take their medication regularly. They will receive recommendations for a healthy lifestyle with low-sugar diet and physical activity, be encouraged to perform routine blood and urine tests and have an eye examination once a year. They will receive by mail a tracking page for documentation of hypoglycemia events. They will be asked to document events of symptomatic low blood sugar (55mg/dl or less) and to indicate whether they needed help to recover from hypoglycemia. They will be told a research assistant will contact them during the follow- up period.
The research assistant will call all participants at one, three, four and six months after the entrance to the study. The patients will be reminded to perform blood tests after three months and six months, to refer to their doctor to get their treatment and prescriptions, and to comply with all other recommendations mentioned above. These frequent calls will be performed to ensure patients safety.
The patients will be asked by phone about symptoms of hypoglycemia with sugar levels of 55 mg/dl or lower, loss of consciousness or need of intervention to increase their blood sugar, what kind of help was needed, and if they went or were taken to the hospital. Severe hypoglycemic events will be reported immediately to the research coordinator, to the attending physician and the ethics committee.
The procedure of the medications bonuses will be arranged in advance with the health maintenance organization (HMO) pharmacies. The patients will get vouchers for buying medications from their doctor or the research staff. Patients from the incentive group will be allowed to receive both bonuses (after three months and after six months) only if they perform their blood tests as scheduled. A patient that will delay his test to four months or more from entry will be entitled only to the first three months bonus. This result will count as the final result for this patient. At six months, participants of all groups will be encouraged to perform their blood tests.
At the end of the trial, data will be collected from the medical records, including HbA1c result, performance of LDL-Cholesterol, triglyceride (TG), albumin-creatinine ratio during the last year test and an eye examination during the last year, consultations with the attending doctor or the diabetic specialist that included prescribing medications for diabetes, name of the patient's clinic, co-morbidities (cardiovascular, respiratory, renal and vascular), diabetes complications, number of medications for diabetes, and prescription of newer medications for diabetes (Dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like peptide glycolipoprotein (GLP) 1 agonists, Sodium-dependent glucose cotransporters (SGLT) 2 inhibitors). Information about hypoglycemia events will be drawn from the medical files as well: episodes of severe hypoglycemia, when the patient needed the help of another person, or capillary blood glucose testing of 55 mg/dl or below accompanied with symptoms, visits to the emergency room attributed to hypoglycemia, Finally, hospitalizations for a week or more, and regular discount for medications due to low income.
The recruitments stage will last one year. Each participant will take part in the study for 6 months, not more than 7 months, till they perform the last blood test. After the last participant performs the final blood test, there will be an ending period for 6 months. Altogether the study will be carried out for two years.
The sample size was estimated for the primary outcome, of 0.55% difference in HbA1c levels between the intervention and the control group, and a 1.2 standard deviation of HbA1c tests of diabetic patients in Clalit Health Services in 2013. In this study, the effect is expected to be higher as in low socioeconomic status patients. To ensure an 80% power to detect differences between arms, and a significance level of 0.05 (two-sided), 76 participants will be needed in each group. To account for dropouts 15% additional participants will be recruited, or a total number of 180 participants.
Any information of severe hypoglycemia will be immediately reported to a research team member to examine the event and to report to the attending physician and the chief investigator. In this situation, the patient's participation in the research will be discontinued, and the event will be reported to the Ethics Committee. In case of death for any reason, it will be reported in detail to the Ethics Committee. An interim analysis will be conducted after half of the study participants (84 people) will finish their study to test the safety of the study.
The researchers will allow visitors on behalf of the ethics committee or regulators to have direct access to information sources and other documents. Monitoring and auditing will take place after half of the participants complete the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Incentives group
a bonus to buy their medications if they improve their HbA1c
Incentives
A bonus to buy their medications if they reduce their HBA1c
Standard group
Will buy their medications as usual
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Incentives
A bonus to buy their medications if they reduce their HBA1c
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diabetes for a maximum of ten years
* Updated HbA1c level of between 8.5 and 11% from the last month
* Agreement to participate and sign an informed consent
Exclusion Criteria
* Insulin therapy
* Psychiatric disorder from the first or second line according to the Diagnostic and Statistical Manual of mental disorders (DSM)
* Active oncology disease \[excluding squamous cell carcinoma (SCC) and basal cell carcinoma (BCC)
* Planed bariatric surgery for the next 6 months
* Cardiac hospitalization in the previous year
* A severe hypoglycemia event three months prior to allocation
40 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Clalit Health Services
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amnon Lahad, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Clalit Health Services
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clalit health services
Jerusalem, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ayelet Prigozin
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Long JA, Jahnle EC, Richardson DM, Loewenstein G, Volpp KG. Peer mentoring and financial incentives to improve glucose control in African American veterans: a randomized trial. Ann Intern Med. 2012 Mar 20;156(6):416-24. doi: 10.7326/0003-4819-156-6-201203200-00004.
Tarasiuk A, Reznor G, Greenberg-Dotan S, Reuveni H. Financial incentive increases CPAP acceptance in patients from low socioeconomic background. PLoS One. 2012;7(3):e33178. doi: 10.1371/journal.pone.0033178. Epub 2012 Mar 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0159-15
Identifier Type: -
Identifier Source: org_study_id